MAGE-C1 Antibody (E-5): sc-377493

MAGE-C1 Antibody (E-5) is a mouse monoclonal IgG1 antibody that detects MAGE-C1 in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). MAGE-C1, also known as CT7, is a member of the melanoma-associated antigen (MAGE) family, characterized by tumor-specific expression primarily in adult tissues, making MAGE-C1 a significant target for cancer immunotherapy. MAGE-C1 is notably expressed in multiple myeloma, where MAGE-C1 correlates with plasma-cell proliferation, highlighting MAGE-C1′s potential role in tumor progression and immune response. MAGE-C1 expression is largely restricted to tumor cells, with normal tissue expression limited to testis and placenta, underscoring MAGE-C1′s importance as a tumor rejection antigen. Understanding MAGE-C1 function in cancer can provide insights into therapeutic strategies aimed at harnessing the immune system to target malignant cells effectively. Anti-MAGE-C1 antibody (E-5) is an essential tool for researchers investigating MAGE-C1′s role in cancer biology and potential as a biomarker for tumor detection and treatment efficacy.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MAGE-C1 Antibody (E-5) References:

1. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.  |  Jungbluth, AA., et al. 2005. Blood. 106: 167-74. PMID: 15761016
2. High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx.  |  Figueiredo, DL., et al. 2011. Head Neck. 33: 702-7. PMID: 20886663
3. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.  |  Anderson, LD., et al. 2011. Cancer Immunol Immunother. 60: 985-97. PMID: 21461886
4. An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients.  |  Inaoka, RJ., et al. 2011. BMC Cancer. 11: 416. PMID: 21951388
5. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.  |  de Carvalho, F., et al. 2011. PLoS One. 6: e27707. PMID: 22110734
6. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma.  |  Errington, JA., et al. 2012. Br J Ophthalmol. 96: 451-8. PMID: 22190731
7. MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients.  |  Nuber, N., et al. 2013. Leukemia. 27: 1767-9. PMID: 23429573
8. Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.  |  Zimmermann, AK., et al. 2013. Virchows Arch. 462: 565-74. PMID: 23529156
9. Sperm protein 17, MAGE-C1 and NY-ESO-1 in hepatocellular carcinoma: expression frequency and their correlation with clinical parameters.  |  Xia, QY., et al. 2013. Int J Clin Exp Pathol. 6: 1610-6. PMID: 23923079
10. Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients.  |  Shires, K. and Wienand, K. 2016. J Cancer Res Clin Oncol. 142: 2383-96. PMID: 27581737

The preferred MAGE-C1 antibody is MAGE-C1 Antibody (CT7-33): sc-53868.